4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces

Related Keywords

United States ,San Francisco ,California ,American ,Julie Seidel ,Biotherapeutic Mrx ,Neil Hunter Michelle Boxall ,Alex Stevenson ,Dominic Wilson ,Philip Davies James Fischer ,Bryan Garnier Co ,Image Box Communications ,Nasdaq ,Exchange Commission ,Merck Co Inc ,United States Securities Exchange ,International Conference ,American Thoracic Society ,Thoracic Society ,Chief Scientific Officer ,Preliminary Signals ,Adult Patients ,Partly Controlled Asthma Treated ,Add On Maintenance Therapy ,Inhaled Corticosteroids ,Without Long Acting Beta Agonists ,Asthma Control Questionnaire ,Asthma Quality ,Life Questionnaire ,United States Securities Act ,United States Securities Exchange Act ,Capital Markets Nominated Adviser ,Joint Broker ,Davies James Fischer ,Corporate Finance ,Corporate Broking ,Hunter Michelle Boxall ,Pharma ,Presents ,Gate ,Breaking ,Abstract ,Rom ,Hase ,Trial ,Dp0004 ,Treatment ,Asthma ,Thoracic ,Society ,022 ,Nternational ,Conference ,